Inactive Instrument

Enzymatica AB Share Price Nasdaq Stockholm

Equities

SE0003943620

Pharmaceuticals

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6M 65.01M 501M Sales 2025 * 11.54M 125M 964M Capitalization 50.24M 545M 4.19B
Net income 2024 * -4M -43.37M -334M Net income 2025 * -1M -10.84M -83.49M EV / Sales 2024 * 8.79 x
Net Debt 2024 * 2.46M 26.68M 205M Net cash position 2025 * 1.65M 17.86M 138M EV / Sales 2025 * 4.21 x
P/E ratio 2024 *
-12.1 x
P/E ratio 2025 *
-20.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.79%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Founder 59 01/07/01
Chief Executive Officer 63 18/17/18
Director of Finance/CFO 55 01/18/01
Members of the board TitleAgeSince
Chairman 62 19/16/19
Director/Board Member 56 15/16/15
Director/Board Member 57 01/21/01
More insiders
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW